TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.

American Journal of Hematology
Vijay RamakrishnanShaji Kumar

Abstract

Interaction of myeloma cells with the bone marrow microenvironment is mediated in large part through different cytokines, especially VEGF and IL6. These cytokines, especially IL6, leads to upregulation of the JAK/STAT pathway in myeloma cell, contributing to increased proliferation, decreased apoptosis, and acquired drug resistance. Here, we examined the preclinical activity of a novel JAK2 inhibitor TG101209. TG101209 induced dose- and time-dependent cytotoxicity in a variety of multiple myeloma (MM) cell lines. The induction of cytotoxicity was associated with inhibition of cell cycle progression and induction of apoptosis in myeloma cell lines and patient-derived plasma cells. Evaluation of U266 cell lines and patient cells, which have a mix of CD45 positive and negative cells, demonstrated more profound cytotoxicity and antiproliferative activity of the drug on the CD45+ population relative to the CD45- cells. Exploring the mechanism of action of TG101209 indicated downregulation of pJak2, pStat3, and Bcl-xl levels with upregulation of pErk and pAkt levels indicating cross talk between signaling pathways. TG101209, when used in combination with the PI3K inhibitor LY294002, demonstrated synergistic cytotoxicity against myelo...Continue Reading

References

Aug 17, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B MeisterR Möhle
Jun 27, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Liang QiaoPaul Dent
Jul 9, 2003·Immunological Reviews·P Leif Bergsagel, W Michael Kuehl
Sep 5, 2003·International Journal of Hematology·Bernard KleinJean François Rossi
Sep 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Alok C BhartiBharat B Aggarwal
Sep 27, 2003·Leukemia·S KumarS V Rajkumar
Mar 9, 2004·Blood Cells, Molecules & Diseases·C Pellat-Deceunynck, R Bataille
Apr 20, 2004·Blood·Teru HideshimaKenneth C Anderson
Jun 23, 2005·British Journal of Cancer·M Amit-VazinaZ Estrov
Jan 11, 2007·Blood·Yijiang ShiAlan Lichtenstein
Jul 25, 2007·Nature Reviews. Cancer·Teru HideshimaKenneth C Anderson
Dec 12, 2007·Best Practice & Research. Clinical Haematology·W J ChngW M Kuehl
Dec 14, 2007·British Journal of Haematology·Robert P EvansTony Reiman
Nov 6, 2009·Experimental & Molecular Medicine·Jinhwa Lee, Sung Soo Kim

❮ Previous
Next ❯

Citations

Aug 8, 2012·Oncogene·W Vainchenker, S N Constantinescu
Jun 16, 2012·Journal of Neuroinflammation·Aedín M MinogueMarina A Lynch
Mar 4, 2014·Nature Chemical Biology·Pietro CiceriStefan Knapp
Aug 18, 2012·Leukemia & Lymphoma·Giada Bianchi, Irene M Ghobrial
Jun 7, 2014·Expert Opinion on Therapeutic Targets·Niamh A KeaneMichael O'Dwyer
Nov 3, 2015·Expert Review of Anticancer Therapy·Maria MoschoviSpiros Vlahopoulos
Apr 13, 2012·Expert Opinion on Investigational Drugs·Brian L HarryAntonio Jimeno
Dec 3, 2010·The Journal of Pathology·William PaoZengliu Su
Feb 29, 2016·Current Hematologic Malignancy Reports·Vijay Ramakrishnan, Anita D'Souza
Aug 19, 2015·Journal of Translational Medicine·Rajesh MukthavaramSantosh Kesari
Oct 27, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Neeraj KumariAnant Narayan Bhatt
Oct 19, 2013·Seminars in Oncology·Panisinee LawasutConstantine S Mitsiades
Aug 26, 2016·Journal of Medicinal Chemistry·Luca Carlino, Giulio Rastelli
Jun 24, 2016·Journal of Clinical and Experimental Hematopathology : JCEH·Masahiro Kizaki, Takayuki Tabayashi
Aug 1, 2011·Therapeutic Advances in Hematology·Nicole Kucine, Ross L Levine
Jan 13, 2018·Leukemia & Lymphoma·Vijay Ramakrishnan, Shaji Kumar
Jan 30, 2019·The Cancer Journal·Shaji K Kumar
Jan 23, 2020·Cancers·Marie Brachet-BotineauFabrice Gouilleux
Mar 11, 2017·Nature Reviews. Drug Discovery·Lenka Munoz
Jun 18, 2019·The Journal of Clinical Investigation·Wei-Zhong YingPaul W Sanders
Oct 19, 2019·Leukemia & Lymphoma·Roberto TammaDomenico Ribatti
Jan 16, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James R BerensonRobert Vescio
Dec 9, 2020·Cancer Letters·Pegah AbdollahiMagne Børset
Dec 8, 2020·American Journal of Physiology. Renal Physiology·Wenguang FengPaul W Sanders

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis